Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 299

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

Open access
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W.K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., Fine, H. A., Mehta, M., DeAngelis, L. M., Lieberman, F., Cloughesy, T. F., Robins, H. I., Dancey, J., Prados, M. D., for the North American Brain Tumor Consortium·2010·Neuro-Oncology

Abstract

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 months for NP GBM post-RT. Secondary objectives for recurrent MGs were response, survival, assessment of toxicity, and pharmacokinetics (PKs). Treatment with enzyme-inducing antiepileptic drugs was not allowed. Patients received 150 mg/day erlotinib. Patients requiring surgery were treated 7 days prior to tumor removal for PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR) and intracellular signaling pathways. Ninety-six patients were evaluable (53 recurrent MG and 43 NP GBM); 5 patients were not evaluable for response. PFS-6 in recurrent GBM was 3% with a median PFS of 2 months; PFS-6 in recurrent AG was 27% with a median PFS of 2 months. Twelve-month survival was 57% in NP GBMs post-RT. Primary toxicity was dermatologic. The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients. No effect on EGFR or intratumoral signaling was seen. Patients with NP GBM post-RT who developed rash in cycle 1 had improved survival (P < .001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nop015

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 299

Metadata

Authors
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., Fine, H. A., Mehta, M., DeAngelis, L. M., Lieberman, F., Cloughesy, T. F., Robins, H. I., Dancey, J., Prados, M. D., & for the North American Brain Tumor Consortium
Venue
Neuro-Oncology
Published
2009-12-14
Volume
12
Issue
1
Pages
95-103
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2160137787
Cited by
299
References
38
FWCI
9.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. https://app.cochat.ai/papers/10.1093/neuonc/nop015
The paper
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., Fine, H. A., Mehta, M., DeAngelis, L. M., Lieberman, F., Cloughesy, T. F., Robins, H. I., Dancey, J., Prados, M. D., & for the North American Brain Tumor Consortium. (2010). A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. https://doi.org/10.1093/neuonc/nop015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.